Skip to main content
ADHERIUM LIMITED logo

ADHERIUM LIMITED — Investor Relations & Filings

Ticker · ADR ISIN · AU000000ADR1 ASX Manufacturing
Open in API
Filings indexed 872 across all filing types
Latest filing 2022-02-22 Regulatory Filings
Country AU Australia
Listing ASX ADR

About ADHERIUM LIMITED

https://www.adherium.com

Adherium Limited is a digital health company specializing in the development and commercialization of connected medical devices and software solutions for chronic respiratory management. The company's primary offering is the Hailie® platform, which consists of advanced sensors that attach to various inhaler medications to monitor usage and technique. These sensors transmit data via Bluetooth to a mobile application and a cloud-based portal, providing patients and healthcare providers with real-time insights into medication adherence and respiratory health trends. By facilitating remote patient monitoring and data-driven clinical decisions, Adherium aims to improve health outcomes for individuals living with asthma and chronic obstructive pulmonary disease (COPD). The platform is utilized by healthcare systems, pharmaceutical companies, and clinical research organizations to enhance patient engagement and optimize treatment efficacy.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - ADR 4 pages 24.3KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the expiry of options (unexercised convertible securities) for Adherium Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an official notification about securities ceasing to exist due to expiry. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-02-22 English
US Respiratory RPM and RTM Reimbursement Rates 4 pages 128.1KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the publication of the 2022 reimbursement rates by the U.S. Centers for Medicare & Medicaid Services (CMS) for Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) CPT codes. It provides detailed information about the reimbursement rates, the significance of these codes for the company's business model, and includes an appendix with code descriptions and rates. The document is not a financial report, audit, or regulatory filing but rather a capital/financing update related to reimbursement rates that impact the company's revenue model. It is not an announcement of a report publication but a substantive update on reimbursement rates relevant to the company's operations and financial prospects. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-02-20 English
Manufacturing started for physiological parameters sensors 3 pages 150.4KB
Regulatory Filings Classification · 90% confidence The document is an announcement from Adherium Limited about the completion of the first production run of a new product, the Hailie for Symbicort sensor with physiological parameters. It discusses product development milestones, manufacturing, market potential, and company strategy. There is no financial data, regulatory filing, or detailed report content. The document is a corporate press release announcing a product manufacturing milestone rather than a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general regulatory announcement or corporate update. Given the absence of a more specific category, the fallback category Regulatory Filings (RNS) is appropriate with high confidence.
2022-02-10 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 372.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report to 31 December 2021' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities. It references the ASX Listing Rule 4.7B, which mandates quarterly cash flow reporting for listed entities in Australia. The content includes actual financial data for the quarter ended 31 December 2021, such as cash on hand, receipts, payments, and other financial metrics. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of detailed financial statements and analysis for a quarter confirms it is an Interim / Quarterly Report. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). Q2 2022
2022-01-27 English
Adherium receives MHRA Registration confirmation 2 pages 127.1KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Adherium has received MHRA Registration confirmation for its Hailie® Sensor medical device in the UK. It discusses regulatory approval and market access but does not contain financial data, management discussion, voting results, or any detailed report content. The document length is short (3174 characters) and it is an announcement rather than a report or filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial or governance disclosures. It is best classified as a Regulatory Filings (RNS) type, which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-01-23 English
Adherium receives $1.6m Australian R&D Tax Incentive 2 pages 117.0KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Adherium Limited has received a $1.6 million Australian R&D Tax Incentive claim for the financial year ending June 30, 2021. It discusses the company's R&D activities and the significance of the tax incentive but does not contain any financial statements, detailed financial performance data, or comprehensive report content. The document is relatively short (3899 characters) and serves as an announcement of a funding receipt rather than a full financial or regulatory report. There is no indication that this is an annual report, interim report, audit report, or any other detailed filing. It is also not a certification or officer attestation. Therefore, the best fitting category is a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2022-01-18 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.